Drug Profile
Mizolastine - sanofi-aventis
Alternative Names: Mistamine; Mizollen; MKC 431; SL 850324; Zolim; ZolistanLatest Information Update: 01 Oct 2007
Price :
$50
*
At a glance
- Originator sanofi-aventis
- Class Antiallergics; Benzimidazoles; Nonsedating antihistamines
- Mechanism of Action Histamine H1 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Allergic conjunctivitis; Allergic rhinitis; Chronic urticaria
- Discontinued Allergic asthma
Most Recent Events
- 01 Oct 2007 Mitsubishi Pharma Corporation has merged with Tanabe Seiyaku to form Mitsubishi Tanabe Pharma Corporation
- 04 Jan 2007 Schwarz Pharma has been acquired by UCB
- 26 Aug 2004 Aventis has merged with Sanofi-Synthelabo to form Sanofi-Aventis